HBV genotype F: Natural history and treatment

Antiviral Therapy

Volumn 18, Issue 3 PARTB, 2013, Pages 485-488

  Marciano, Sebastián ^a   Galdame, Omar A ^a   Gadano, Adrián C ^a  

^a HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

DRUG EFFICACY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HISTORY OF MEDICINE; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84879630148     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2604     Document Type: Review

References (20)

1. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185.
2. Ge D, Fellay J, Thompson A, et al. Genetic variation in IL28B predict hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
3. Tanaka Y, Nishida N, Sugiyama N, et al. Genome-wide association of IL28B with response to pegylated-interferon alpha with and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
4. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
5. Ridruejo E, Solano A, Marciano S. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol 2011; 10:452-457.
6. Allain J. Epidemiology of hepatitis B virus and genotype. J Clin Virol 2006; 36 Suppl 1:S12-S17.
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
8. Duong TN, Horiike N, Michitaka K, et al. Comparison of genotypes C and D of the hepatitis B virus in Japan: a clinical and molecular biological study. J Med Virol 2004; 72:551-557.
9. Tsubota A, Arase Y, Ren F, et al. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw. J Med Virol 2001; 65:257-265.
10. Yu M W, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265-272.
11. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:1134-1143.
12. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123:1848-1856.
13. Pezzano SC, Torres C, Fainboim HA, et al. Hepatitis B virus in Buenos Aires, Argentina: genotypes, virological characteristics and clinical outcomes. Clin Microbiol Infect 2011; 17:223-231.
14. Livingston S, Simonetti J, McMahon B, et al. Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F. J Iinfect Dis 2007; 195:5-11.
15. Osiowy C, Simons BC, Rempel JD. Distribution of viral hepatitis in indigenous populations of North America and the circumpolar Arctic. Antivir Ther 2013; 18:467-473.
16. Laufer N, Quarleri J, Bouzas M, et al. Hepatitis B virus, hepatitis C virus and HIV coinfection among people living with HIV/AIDS in Buenos Aires, Argentina. Sex Transm Dis 2010; 37:342-343.
17. Gomes-Gouvêa MS, Soares MC, Bensabath G, et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. J Gen Virol 2009; 90:2638-2643.
18. Raimondi S, Maisonneuve P, Bruno S, Mondelli M. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol 2010; 52:441-449.
19. Solari J, Galdame O, Rezzonico L, et al. [24-Week therapy with peginterferon alfa-2a could be similar to 48 week therapy in patients with HBeAg positive chronic hepatitis B and good predictors of response: results of a pilot study]. Acta Gastroenterol Latinoam 2009; 39:254-260. Spanish.
20. Alvarado-Mora M V, Rebello Pinho JR. Distribution of HBV genotypes in Latin America. Antivir Ther 2013; 18:459-465.